Week 96 Results of Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV Treatment in People With Substance Use Disorders

Overview

Journal Open Forum Infect Dis

Date 2025 Jan 10

PMID 39790640

Authors

Joshua P Havens

Sara H Bares

Elizabeth Lyden

Nada Fadul

Susan Swindells

Affiliations

Soon will be listed here.

Abstract

Background: The BASE study (NCT03998176), a phase 4, 48-week (W), single-arm, prospective trial, revealed that the use of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people with HIV and substance use disorders (PWH/SUD) was safe and effective without emergent antiretroviral resistance despite incomplete adherence. Here, we present the W96 results.

Methods: A retrospective analysis of all participants enrolled in the BASE study was completed from W48 to W96. End points of interest at W96 included the proportion of participants with viral suppression (VS; HIV RNA <50 copies/mL [c/mL]), incidence of protocol-defined virologic failure (PDVF; 2 consecutive ≥400 c/mL), safety, adherence (percentage of days covered [PDC]), retention in care, and prevalence of ongoing substance use.

Results: All enrolled BASE participants (n = 43) were included in the W96 analysis. At W48, 21 participants (49%) had achieved VS (intent-to-treat [ITT]). Thirty-six (84%) participants completed W96, with 19 achieving an HIV RNA <50 copies/mL (ITT, 44%; per-protocol, 54%). Seven participants (19%) met PDVF; genotyping was performed on 2, with no evidence of treatment-emergent antiretroviral resistance noted. No safety signals were identified or attributed to B/F/TAF. Adherence to B/F/TAF decreased 18% after W48 (mean PDC: W0-W48, 72%; W48-W96, 54%; < .01). Participants exhibiting adherence rates of ≥4 doses/wk (PDC ≥57%) were more likely to achieve VS (PDC ≥57%, 84.2%, vs PDC <57%, 15.8%; < .01). Retention in care remained stable, and participants continued to use substances through W96.

Conclusions: At W96, the proportion of PWH/SUD achieving VS with B/F/TAF decreased to 44%, along with an adherence decrease of 18%, with no evidence of treatment-emergent HIV drug resistance occurring.

References

Nyein P, Petoumenos K, Borok M, Eriobu N, Kumarasamy N, Avihingsanon A . Associations Between Antiretroviral Regimen and Changes in Blood Pressure: Results From the D2EFT Study. Clin Infect Dis. 2024; 80(1):160-163. PMC: 11797029. DOI: 10.1093/cid/ciae256. View

Pinto R, Hall E, Tomlin R . Injectable Long-Acting Cabotegravir-Rilpivirine Therapy for People Living With HIV/AIDS: Addressing Implementation Barriers From the Start. J Assoc Nurses AIDS Care. 2023; 34(2):216-220. PMC: 9951790. DOI: 10.1097/JNC.0000000000000386. View

Perez A, Nieves S, Meisner J . Implementation of Injectable Cabotegravir/Rilpivirine for Treatment of Human Immunodeficiency Virus in Patients With Substance Use Disorders at a Syringe Exchange Clinic. Open Forum Infect Dis. 2024; 11(11):ofae640. PMC: 11565405. DOI: 10.1093/ofid/ofae640. View

Fauci A, Redfield R, Sigounas G, Weahkee M, Giroir B . Ending the HIV Epidemic: A Plan for the United States. JAMA. 2019; 321(9):844-845. DOI: 10.1001/jama.2019.1343. View

Esser S, Brunetta J, Inciarte A, Levy I, Monforte A, Lambert J . Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real-world insights from BICSTaR cohorts. HIV Med. 2023; 25(4):440-453. DOI: 10.1111/hiv.13593. View

Meyer J, Althoff A, Altice F . Optimizing care for HIV-infected people who use drugs: evidence-based approaches to overcoming healthcare disparities. Clin Infect Dis. 2013; 57(9):1309-17. PMC: 3792721. DOI: 10.1093/cid/cit427. View

Havens J, Bares S, Lyden E, Podany A, Scarsi K, Fadul N . Effectiveness and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Patients With HIV-1 Infection and Ongoing Substance Use Disorder: The BASE Study. Open Forum Infect Dis. 2023; 10(3):ofad080. PMC: 10003752. DOI: 10.1093/ofid/ofad080. View

Venter W, Sokhela S, Simmons B, Moorhouse M, Fairlie L, Mashabane N . Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised,.... Lancet HIV. 2020; 7(10):e666-e676. DOI: 10.1016/S2352-3018(20)30241-1. View

Hartzler B, Dombrowski J, Williams J, Crane H, Eron J, Geng E . Influence of Substance Use Disorders on 2-Year HIV Care Retention in the United States. AIDS Behav. 2017; 22(3):742-751. PMC: 5729068. DOI: 10.1007/s10461-017-1826-2. View

10.

Adams J, Marshall B, Mohd Salleh N, Barrios R, Nolan S, Milloy M . Receipt of opioid agonist treatment halves the risk of HIV-1 RNA viral load rebound through improved ART adherence for HIV-infected women who use illicit drugs. Drug Alcohol Depend. 2019; 206:107670. PMC: 7012150. DOI: 10.1016/j.drugalcdep.2019.107670. View

11.

Zhang Y, Wilson T, Adedimeji A, Merenstein D, Milam J, Cohen J . The Impact of Substance Use on Adherence to Antiretroviral Therapy Among HIV-Infected Women in the United States. AIDS Behav. 2017; 22(3):896-908. PMC: 5709246. DOI: 10.1007/s10461-017-1808-4. View

12.

Sax P, Pozniak A, Montes M, Koenig E, DeJesus E, Stellbrink H . Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3,.... Lancet. 2017; 390(10107):2073-2082. DOI: 10.1016/S0140-6736(17)32340-1. View

13.

Stringer K, Marotta P, Baker E, Turan B, Kempf M, Drentea P . Substance Use Stigma and Antiretroviral Therapy Adherence Among a Drug-Using Population Living with HIV. AIDS Patient Care STDS. 2019; 33(6):282-293. PMC: 6588110. DOI: 10.1089/apc.2018.0311. View

14.

Leierer G, Grabmeier-Pfistershammer K, Steuer A, Geit M, Sarcletti M, Haas B . Factors Associated with Low-Level Viraemia and Virological Failure: Results from the Austrian HIV Cohort Study. PLoS One. 2015; 10(11):e0142923. PMC: 4643888. DOI: 10.1371/journal.pone.0142923. View

15.

Hartzler B, Dombrowski J, Crane H, Eron J, Geng E, Mathews W . Prevalence and Predictors of Substance Use Disorders Among HIV Care Enrollees in the United States. AIDS Behav. 2016; 21(4):1138-1148. PMC: 6089366. DOI: 10.1007/s10461-016-1584-6. View

16.

Shubber Z, Mills E, Nachega J, Vreeman R, Freitas M, Bock P . Patient-Reported Barriers to Adherence to Antiretroviral Therapy: A Systematic Review and Meta-Analysis. PLoS Med. 2016; 13(11):e1002183. PMC: 5127502. DOI: 10.1371/journal.pmed.1002183. View

17.

Liang J, Nosova E, Reddon H, Nolan S, Socias E, Barrios R . Longitudinal patterns of illicit drug use, antiretroviral therapy exposure and plasma HIV-1 RNA viral load among HIV-positive people who use illicit drugs. AIDS. 2020; 34(9):1389-1396. PMC: 7869847. DOI: 10.1097/QAD.0000000000002551. View

18.

Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P . Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017; 390(10107):2063-2072. DOI: 10.1016/S0140-6736(17)32299-7. View

19.

Sax P, Erlandson K, Lake J, McComsey G, Orkin C, Esser S . Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. Clin Infect Dis. 2019; 71(6):1379-1389. PMC: 7486849. DOI: 10.1093/cid/ciz999. View

20.

Landman R, De Truchis P, Assoumou L, Lambert S, Bellet J, Amat K . A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial. Lancet HIV. 2022; 9(2):e79-e90. DOI: 10.1016/S2352-3018(21)00300-3. View